Luye Pharma Group Ltd.
LYPHF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Revenue | $3,181,110 | $2,986,859 | $3,074,582 | $3,238,970 |
| % Growth | 6.5% | -2.9% | -5.1% | – |
| Cost of Goods Sold | $1,023,501 | $1,021,182 | $996,032 | $978,158 |
| Gross Profit | $2,157,609 | $1,965,677 | $2,078,550 | $2,260,812 |
| % Margin | 67.8% | 65.8% | 67.6% | 69.8% |
| R&D Expenses | $193,417 | $217,679 | $280,908 | $291,002 |
| G&A Expenses | $315,486 | $292,783 | $289,179 | $346,623 |
| SG&A Expenses | $1,334,302 | $1,258,385 | $1,140,005 | $1,287,545 |
| Sales & Mktg Exp. | $1,018,816 | $965,602 | $850,826 | $940,922 |
| Other Operating Expenses | $0 | -$143,805 | $0 | $0 |
| Operating Expenses | $1,527,719 | $1,332,259 | $1,420,913 | $1,578,547 |
| Operating Income | $629,890 | $633,418 | $657,637 | $682,265 |
| % Margin | 19.8% | 21.2% | 21.4% | 21.1% |
| Other Income/Exp. Net | -$172,250 | -$324,176 | -$127,660 | -$211,153 |
| Pre-Tax Income | $457,640 | $309,242 | $529,977 | $471,112 |
| Tax Expense | $100,257 | $102,412 | $91,799 | $77,389 |
| Net Income | $312,886 | $84,050 | $387,836 | $382,628 |
| % Margin | 9.8% | 2.8% | 12.6% | 11.8% |
| EPS | 0.083 | -0.083 | 0.1 | 0.102 |
| % Growth | 200.8% | -182.5% | -1.8% | – |
| EPS Diluted | 0.083 | -0.083 | 0.1 | 0.102 |
| Weighted Avg Shares Out | 3,761,689 | 3,761,671 | 3,761,782 | 3,762,247 |
| Weighted Avg Shares Out Dil | 3,761,671 | 3,761,671 | 3,761,671 | 3,762,223 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $84,432 | $0 | $209,940 |
| Interest Expense | $0 | $561,785 | $0 | $0 |
| Depreciation & Amortization | $393,244 | $455,739 | $334,933 | $348,291 |
| EBITDA | $1,003,569 | $1,252,206 | $939,470 | $1,028,627 |
| % Margin | 31.5% | 41.9% | 30.6% | 31.8% |